Sarah Ketterer
Causeway Capital Management
Sarah Ketterer Merck & Company Inc stake
total: 372
Causeway Capital Management MRK trades
- Total transactions:
- 14
- New positions:
- 2
- Sold out:
- 1
- Added:
- 6
- Reduced:
- 5
- Held since:
- 2024 Q4
- Held for:
- 7 quarters
- Latest activity:
- 2026 Q2
According to 2026 Q2 report, Sarah Ketterer holds 954,932 Merck & Company Inc (MRK) shares with a market value of roughly $122.71M accounting for 1.33% of the overall portfolio. To date, the estimated cost basis is nearly $96.08 for "buy" trades and estimated average "sell" price is $115.49. Causeway Capital Management first purchased MRK in 2019 Q1, initially acquiring about 1.74M shares. Sarah Ketterer later completely sold out the position and invested in Merck & Company Inc again in 2024 Q4. Since the initial investment in Merck & Company Inc (MRK), Causeway Capital Management has made 13 more transactions.
When did Sarah Ketterer buy Merck & Company Inc (MRK)?
Sarah Ketterer first invested in Merck & Company Inc (MRK) in 2019 Q1 at the reported quarter-end price of $83.17 per share.
What's the cost basis of Causeway Capital Management's MRK stake?
The estimated cost basis for Merck & Company Inc (MRK) stake is around $96.08 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $96.08
- Weighted AVG sell price:
- $115.49
Sarah Ketterer's historical trades in Merck & Company Inc
14 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
1.33%
|
954,932
|
$128.50
|
$122,708,787
|
+11.79% (+100,720)
|
+0.14%
|
|
2026 Q1
|
1.26%
|
854,212
|
$120.29
|
$102,753,243
|
-18.23% (-190,405)
|
-0.32%
|
|
2025 Q4
|
1.51%
|
1,044,617
|
$105.26
|
$109,956,449
|
-7.89% (-89,440)
|
-0.12%
|
|
2025 Q3
|
1.26%
|
1,134,057
|
$83.93
|
$95,181,306
|
+15.41% (+151,397)
|
+0.17%
|
|
2025 Q2
|
1.23%
|
982,660
|
$79.16
|
$77,787,310
|
+9.44% (+84,791)
|
+0.11%
|
|
2025 Q1
|
1.68%
|
897,869
|
$89.76
|
$80,592,684
|
+53.62% (+313,396)
|
+0.59%
|
|
2024 Q4
|
1.32%
|
584,473
|
$99.48
|
$58,143,366
|
new
|
+1.32%
|
|
2020 Q3
|
0.00%
|
$77.33
|
-100% (-814,074)
|
|||
|
2020 Q2
|
1.13%
|
$77.33
|
-44.05% (-640,968)
|
|||
|
2020 Q1
|
1.79%
|
$76.94
|
-17.80% (-315,068)
|
|||
|
2019 Q4
|
1.73%
|
$90.95
|
-3.25% (-59,475)
|
|||
|
2019 Q3
|
1.84%
|
$84.18
|
+3.95% (+69,530)
|
|||
|
2019 Q2
|
1.62%
|
$83.85
|
+0.98% (+17,086)
|
|||
|
2019 Q1
|
1.46%
|
$83.17
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.